San Francisco-based Siren Biotechnology secured USD 8 million in clinical-stage funding from CIRM to initiate a Phase I/II study of its AAV immuno-gene therapy SRN-101 in recurrent high-grade glioma, extending state support following FDA clearance of the program's IND earlier this year. The award extends CIRM's prior USD 4 million translational-stage support for the same program.
SRN-101 uses an AAV vector to drive sustained local expression of immune-modulating payloads within tumors, an approach intended to overcome the limited durability and systemic toxicity associated with many immunotherapies. The program holds FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Intratumoral gene therapy approaches for glioma face competition from platforms including Tocagen's retroviral delivery work and various oncolytic virus programs, though AAV-based immuno-oncology delivery at the clinical stage remains relatively uncommon.
CIRM's decision to follow its translational grant with a larger clinical-stage award signals continued state-level confidence in AAV-based oncology approaches, a modality that has seen increased interest as gene therapy manufacturing and delivery technologies mature.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article